Description

ARMOTRAZ 1 MG

Indications

ARMOTRAZ 1 MG is primarily indicated for the treatment of postmenopausal women with hormone receptor-positive breast cancer. It is particularly useful in patients who have experienced disease progression following tamoxifen therapy. ARMOTRAZ is also indicated for the adjuvant treatment of early breast cancer in postmenopausal women, enhancing the effectiveness of surgical and radiotherapeutic interventions.

Mechanism of Action

ARMOTRAZ contains anastrozole, a non-steroidal aromatase inhibitor that works by inhibiting the aromatase enzyme. This enzyme is crucial for the conversion of androgens to estrogens in peripheral tissues, particularly in postmenopausal women where ovarian estrogen production has ceased. By reducing estrogen levels in the body, ARMOTRAZ effectively deprives estrogen-dependent tumors of the hormone necessary for their growth and proliferation, thereby slowing or halting the progression of breast cancer.

Pharmacological Properties

ARMOTRAZ is rapidly absorbed after oral administration, with peak plasma concentrations occurring within 2 hours. It has a half-life of approximately 50 hours, allowing for once-daily dosing. The drug is extensively metabolized in the liver, primarily via cytochrome P450 2.3 (CYP2.3) pathway, and its metabolites are excreted mainly in urine. The pharmacokinetics of ARMOTRAZ are not significantly affected by food intake, making it convenient for patients to incorporate into their daily routines.

Contraindications

ARMOTRAZ is contraindicated in patients with a known hypersensitivity to anastrozole or any of the excipients in the formulation. It should not be used in premenopausal women, as the mechanism of action is specific to postmenopausal estrogen production. Additionally, ARMOTRAZ is contraindicated during pregnancy and lactation due to potential harm to the fetus or nursing infant.

Side Effects

Common side effects associated with ARMOTRAZ include hot flashes, joint pain, fatigue, and nausea. Other less common but more serious side effects may include bone density loss, which can lead to osteoporosis and fractures, cardiovascular events, and liver function abnormalities. Patients should be monitored regularly for these adverse effects, and any significant changes should be reported to a healthcare provider promptly.

Dosage and Administration

The recommended dosage of ARMOTRAZ is 1 MG taken orally once daily, with or without food. Treatment should be continued until disease progression is evident or until the patient experiences unacceptable toxicity. It is essential for patients to adhere to the prescribed regimen to maximize the therapeutic benefits of the medication. In cases of missed doses, patients should take the dose as soon as they remember, but if it is close to the time for the next dose, they should skip the missed dose and resume their regular schedule. Doubling the dose to make up for a missed one is not advised.

Interactions

ARMOTRAZ may interact with other medications, particularly those that are metabolized by the CYP450 enzyme system. Strong inducers or inhibitors of CYP2.3 can significantly alter the plasma concentrations of anastrozole. Drugs such as tamoxifen, estrogen-containing therapies, and certain anticonvulsants may reduce the efficacy of ARMOTRAZ. Patients should inform their healthcare provider of all medications, supplements, and herbal products they are taking to avoid potential interactions.

Precautions

Patients with a history of osteoporosis or those at risk for bone density loss should be closely monitored while on ARMOTRAZ. It is advisable to assess bone mineral density before initiating treatment and periodically thereafter. Additionally, caution should be exercised in patients with hepatic impairment, as the metabolism of anastrozole may be affected. Regular monitoring of liver function tests is recommended for these patients. Women of childbearing potential should be advised to use effective contraception during treatment and for at least 3 weeks after discontinuing ARMOTRAZ.

Clinical Studies

Clinical trials have demonstrated the efficacy of ARMOTRAZ in improving outcomes for postmenopausal women with hormone receptor-positive breast cancer. In a pivotal study published in the New England Journal of Medicine, ARMOTRAZ was shown to be superior to tamoxifen in terms of disease-free survival and overall survival rates. Further studies have confirmed its role in both adjuvant settings and in the treatment of advanced breast cancer, establishing ARMOTRAZ as a cornerstone in the management of this disease.

Conclusion

ARMOTRAZ 1 MG is a vital therapeutic option for postmenopausal women with hormone receptor-positive breast cancer. Its mechanism of action as an aromatase inhibitor effectively lowers estrogen levels, which is crucial for the management of estrogen-dependent tumors. While it is generally well-tolerated, healthcare providers must monitor patients for side effects and potential drug interactions. With proper management, ARMOTRAZ can significantly improve clinical outcomes and quality of life for patients undergoing treatment for breast cancer.